BioRestorative Therapies (BRT), a US-based stem cell biotechnology company, has brought in product design and bioengineering firm Dexterity to further the production of its proprietary therapeutic delivery device.

The two companies have signed a consulting agreement, under which Dexterity is responsible for taking the design and production of the device, intended for its intervertebral disc stem cell therapy programme, brtxDISC, to a final version.

Dexterity president Eric Simon said, "Our experience with laparascopic and catheter-based devices, cell culture systems, and drug-delivery devices will assist in advancing the development and production of BRTX’s disc stem cell delivery device as the company moves through its next phase of clinical trials."

BRT, which is looking for a pre-IND/IDE meeting with the FDA to discuss the clinical trial by fourth quarter of this year, said the programme has been developed as an alternate option for surgical intervention while treating patients with bulging and herniated discs.

As part of the regeneration repair process, BRT’s proprietary therapeutic delivery device will implant patient’s own stem cells.

The therapy will also bridge the gap between non-invasive and invasive surgical back procedures, said the company.

BioRestorative Therapies chief executive officer Mark Weinreb said the company is confident in its device’s performance and quality to operate as intended and will be commercial-ready when brtxDISC programme is launched.

"With their depth of experience in 3D-CAD, biomaterials, and advanced prototyping and manufacturing, they are the perfect partner to work on the design and final engineering of our medical disc delivery device," Weinreb added.